Burning Rock Biotech (NASDAQ:BNR) Posts Quarterly Earnings Results

Burning Rock Biotech (NASDAQ:BNR) posted its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, Zacks reports. Burning Rock Biotech had a negative net margin of 26.04% and a negative return on equity of 23.61%.

Burning Rock Biotech Price Performance

BNR traded up $2.07 during midday trading on Thursday, reaching $18.10. 17,549 shares of the company’s stock were exchanged, compared to its average volume of 31,103. Burning Rock Biotech has a 1-year low of $2.18 and a 1-year high of $18.51. The stock has a market capitalization of $194.76 million, a PE ratio of -9.52 and a beta of 1.11. The business’s 50-day moving average price is $10.31 and its 200 day moving average price is $6.92.

Analyst Ratings Changes

Several research firms recently weighed in on BNR. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Burning Rock Biotech to a “buy” rating in a report on Saturday, November 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Burning Rock Biotech presently has an average rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.